Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Fufang E'Jiao Jiang

PreclinicalSmall molecule

XXiyuan Hospital of China Academy of Chinese Medical Sciences

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q3 2027

N/ANot yet recruiting

Critically Ill Patients

NCT07157748

Clinical

Trials by Indication[1]

Fatigue1 trial

Fufang E'Jiao Jiang Intervening Cancer-related Fatigue

Unknown status·XXiyuan Hospital of China Academy of Chinese Medical Sciences·N/A·NCT04147312·600 enrolled

Critically Ill Patients1 trial

Effects of Compound Ejiao Syrup on Exercise Tolerance and Quality of Life in Critically Ill Patients After ICU Discharge: A Double-Blind, Multicenter,Randomized Controlled Clinical Study

Not yet recruiting·TThird Military Medical University·N/A·NCT07157748·178 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Fufang E'Jiao Jiang. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fufang E'Jiao Jiang compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fufang E'Jiao Jiang. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xiyuan Hospital of China Academy of Chinese Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: XXiyuan Hospital of China Academy of Chinese Medical Sciences

Related News